Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment

BACKGROUND: Solriamfetol, a dopamine-norepinephrine reuptake inhibitor, is approved in the United States to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with OSA (37.5-150 mg/d). RESEARCH QUESTION: Does solriamfetol have differential effects on EDS based on adhere...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweitzer, Paula K., Mayer, Geert, Rosenberg, Russell, Malhotra, Atul, Zammit, Gary K., Gotfried, Mark, Chandler, Patricia, Baladi, Michelle, Strohl, Kingman P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians 2021
Materias:
Sleep: Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411452/
https://www.ncbi.nlm.nih.gov/pubmed/33631141
http://dx.doi.org/10.1016/j.chest.2021.02.033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8411452/
https://www.ncbi.nlm.nih.gov/pubmed/33631141
http://dx.doi.org/10.1016/j.chest.2021.02.033

Ejemplares similares